Related Experiment Video
Updated: Jun 23, 2026
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Gene expression profiling of ErbB receptors and ligands in human meningiomas
Ingrid Laurendeau1, Marcela Ferrer, Delia Garrido
1UMR745, INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris-Descartes, Paris, France.
Abstract:
ErbB family receptors mediate major cellular functions implied in tumorigenesis, though their role in meningiomas was not thoroughly studied. Meningiomas represent 30% of primary cranial tumors, are mostly benign, and prevail in the second half of life. Tumor therapy requires information about molecular alterations, thus we studied expression of ErbB receptor and ligand genes by real-time RT-PCR in different meningioma grades. Receptors were overexpressed (ErbB1, ErbB2) or underexpressed (ErbB3, ErbB4). Ligands EGF, TGFA, AREG, DTR, BTD were underexpressed and the neuregulins were overexpressed or underexpressed. A strong ErbB1-ErbB2 correlation was found. These data might be useful for gene therapy.
Insights
This study investigated ErbB receptor and ligand gene expression in meningiomas, revealing altered levels of key molecules like ErbB1 and ErbB2. These findings may inform future gene therapy strategies for cranial tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Meningiomas are common primary cranial tumors, often benign, predominantly affecting middle-aged and older adults.
- The ErbB receptor family plays a crucial role in cell signaling and tumorigenesis, but their specific involvement in meningiomas requires further elucidation.
- Understanding molecular alterations in meningiomas is essential for developing effective tumor therapies.
Purpose of the Study:
- To investigate the expression patterns of ErbB receptor and ligand genes in different grades of meningioma.
- To identify potential molecular targets for gene therapy in meningioma treatment.
Main Methods:
- Real-time reverse transcription polymerase chain reaction (RT-PCR) was employed to quantify gene expression levels.
- Analysis was performed across various grades of meningioma tissue samples.
Main Results:
- Significant alterations in ErbB receptor expression were observed, with ErbB1 and ErbB2 showing overexpression and ErbB3 and ErbB4 exhibiting underexpression.
- Differential expression patterns were noted for ErbB ligands, including epidermal growth factor (EGF), transforming growth factor alpha (TGFA), and amphiregulin (AREG).
- A strong positive correlation was identified between ErbB1 and ErbB2 expression levels.
Conclusions:
- The study highlights significant dysregulation of ErbB signaling pathways in meningiomas.
- Observed gene expression profiles, particularly the overexpression of ErbB1 and ErbB2, suggest their potential as therapeutic targets.
- These findings provide a molecular basis for exploring gene therapy approaches in meningioma management.
